AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65Mnews2024-10-31T12:00:02+00:00October 31st, 2024|Endpoints News|
Another Paragon offshoot inks reverse merger as Jade takes Aerovate’s placenews2024-10-31T11:27:04+00:00October 31st, 2024|Endpoints News|
Blue Earth Therapeutics snags $76M for both alpha and beta radiotherapiesnews2024-10-30T12:00:15+00:00October 30th, 2024|Endpoints News|
Nobel winner David Baker co-founds another startup, as Archon takes an AI twist on antibodiesnews2024-10-30T11:00:26+00:00October 30th, 2024|Endpoints News|
Axonis snags $115M to test oral drugs for epilepsy and neuropathic painnews2024-10-30T10:00:24+00:00October 30th, 2024|Endpoints News|
Corrected: Genmab lines up T cell engager pact with Revitopenews2024-10-29T11:15:59+00:00October 29th, 2024|Endpoints News|
AbbVie makes $1.4B acquisition of Alzheimer’s biotechnews2024-10-28T14:27:08+00:00October 28th, 2024|Endpoints News|
Synaffix launches startup with pipeline of ADC drugs and $92Mnews2024-10-28T12:00:06+00:00October 28th, 2024|Endpoints News|
Former Seagen CEO David Epstein to lead new biotech with VEGF bifunctional antibodynews2024-10-28T11:29:10+00:00October 28th, 2024|Endpoints News|
FogPharma rebrands as Parabilis, highlighting next drugsnews2024-10-28T11:00:44+00:00October 28th, 2024|Endpoints News|
